1.Serum erythropoietin and tumor necrosis factor ?in neoplasms, chronic inflammatory disorders, and iron deficiency anemias.
Jong Ho WON ; Dong Jip RA ; Dae Sik HONG ; Hee Sook PARK
Korean Journal of Medicine 1993;45(5):579-587
No abstract available.
Anemia, Iron-Deficiency*
;
Erythropoietin*
;
Iron*
;
Tumor Necrosis Factor-alpha*
2.5 cases of chronic lymphocytic leukemia with diverse clinical manifestations.
Dong Jip RA ; Jong Bong KIM ; Jong Ho WON ; Dae Sik HONG ; Hee Sook PARK ; Won Bae KIM
Korean Journal of Hematology 1992;27(1):81-88
No abstract available.
Leukemia, Lymphocytic, Chronic, B-Cell*
3.Effects of ondansertron in the prevention of nausea and vomiting associated with chemotherapy in acute myelocytic leukemia.
Woo Sung MIN ; Jong Youl JIN ; Chi Wha HAN ; Chong Won PARK ; Chun Choo KIM ; Dong Jip KIM
Journal of the Korean Cancer Association 1992;24(2):288-292
No abstract available.
Drug Therapy*
;
Leukemia, Myeloid, Acute*
;
Nausea*
;
Vomiting*
4.Revisiting anemia afer ABO-mismatched allogeneic bone marrow transplantation.
Gyu Taek LIM ; Dong Wook KIM ; Jong Youl JIN ; Jong Wook LEE ; Chi Wha HAN ; Woo Sung MIN ; Chong Won PARK ; Choon Choo KIM ; Dog Jip KIM
Korean Journal of Hematology 1991;26(1):13-21
No abstract available.
Anemia*
;
Bone Marrow Transplantation*
;
Bone Marrow*
5.The effect on somatostatin for patients with diarrhea caused by intensive chemotheray of acute graft-cersus-host reaction after allogeneic bone marrow transplantation.
Hee Je KIM ; Jong Youl LEE ; Jong Wook JIN ; Chi Wha HAN ; Woo Sung MIN ; Chong Won PARK ; Chun Choo KIM ; Dong Jip KIM
Korean Journal of Hematology 1992;27(1):41-46
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*
;
Diarrhea*
;
Humans
;
Somatostatin*
6.Introduction of a new therapeutic modality for SLE patients accompanying severe life-threatening hematologic complications.
Seok Goo CHO ; Jong Youl JIN ; Jong Wook LEE ; Chi Wha HAN ; Woo Seong MIN ; Chong Won PARK ; Chun Choo KIM ; Dong Jip KIM
Korean Journal of Hematology 1991;26(1):151-160
No abstract available.
Humans
7.Preliminary study of antithymocyte or antilymphocyte globulin, cyclosporine-A and recombinant human granulocyte macrophage colony stimulating factors for patients with aplastic anemia.
Dong Wook KIM ; Jong Youl JIN ; Jong Wook LEE ; Chi Wha HAN ; Woo Sung MIN ; Hack Ki KIM ; Chong Won PARK ; Chun Choo KIM ; Dong Jip KIM
Korean Journal of Hematology 1992;27(2):233-237
No abstract available.
Anemia, Aplastic*
;
Antilymphocyte Serum*
;
Granulocyte-Macrophage Colony-Stimulating Factor*
;
Granulocytes*
;
Humans*
8.A case of non-Hodgkin's lymphoma developed after radiotherapy in Hodgkin's disease.
Young Boo PARK ; Jin Hyoung KANG ; Jong Youl JIN ; Hoon Kyo KIM ; Kyung Shik LEE ; Dong Jip KIM ; Byung Kee KIM ; Sun Moo KIM
Journal of the Korean Cancer Association 1992;24(2):338-342
No abstract available.
Hodgkin Disease*
;
Lymphoma, Non-Hodgkin*
;
Radiotherapy*
9.Effect of All - trans Retinoic Acid ( ATRA ) on the Remission Induction and Coaguloyathy in Acute Promyelocytic Leukemia ( APL ).
Sung Gwon KIM ; Chi Wha HAN ; Yoo Jin KIM ; Dong Wook KIM ; Jong Youl JIN ; Woo Sung MIN ; Chong Won PARK ; Choon Choo KIM ; Dong Jip KIM
Korean Journal of Medicine 1997;53(2):199-206
OBJECTIVES: APL, which characteristically shows t(15:17), accompanies fatal coagulopathy during remission induction with systemic chemotherapy alone. ATRA, a derivative of vitamin A, can differentiate APL cells as well as HL-60 cells in vitro and induce higher rate of complete remission(CR). Hence, we assessed the effect of ATRA on remission induction and coagulopathy in APL patients. METHODS: (1) 42 patients diagnosed histologically in St. mary's hospital from June 1991 to June 1994 were included. (2) We compared the CR rate, the time required for restoration of derranged coagulation profiles, and the amount of coagulation factors including platelets among the chemotherapy group (control) and ATRA group. RESULTS: 1) There was no difference in CR rate between the control group and ATRA group [84.2%(16 out of 19) vs 87.0%(20 out of 23), p>0.05)] and also no difference between two subgroups of ATRA [ATRA with chemotherapy; 83.3%(10 out of 12) vs ATRA without chemotherapy; 90.9%(10 out of 11), p>0.05] 2) In the ATRA group, the CR rate of newly diagnosed patients was 82.4%(14 out of 17). The first relapsed patients (4) and the second (2) were all achieved CR. 3) The mean duration of coagulopathy, time to normalization of PT, aPTT, FDP, fibrinogen level, was 12.0+/-10.4, 11.1+/-10.2, 16.5+/-9.3, 15.4+/-10.2 days after chemotherapy alone and 4.5+/-4.4, 3.7+/-3.7, 8.9+/-6.1, 8.1+/-6.5 days in the ATRA group(p<0.05). The amount of fresh frozen plasma used in the ATRA group for the purpose of correction of coagulopathy were significantly lower than the control group(p<0.05). The incidence of profound coagulopathy during the remission induction treatment in the ATRA group was significantly lower than the control group[40% (8 out of 20) vs 96.7%(13 out of 15), p
Blood Coagulation Factors
;
Drug Therapy
;
Fibrinogen
;
HL-60 Cells
;
Humans
;
Incidence
;
Leukemia, Promyelocytic, Acute*
;
Plasma
;
Remission Induction*
;
Tretinoin*
;
Vitamin A
10.Unusual complications after allogeneic bone marrow transplantation.
Hyun Bok HAN ; Jong Wook LEE ; Chi Wha HAN ; Woo Sung MIN ; Chong Won PARK ; Choon Choo KIM ; Dong Jip KIM
Korean Journal of Hematology 1991;26(2):339-347
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*